Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Virology Journal

Fig. 4

From: Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines

Fig. 4

Direct oncolytic effect of intratumoral CV-B3/2035A administration on EC xenografts in vivo. Nude mice bearing HEC-1-A (a, b), HEC-1-B (c, d) and Ishikawa (e, f) xenografts were treated intratumorally (i.t.) with either a single or five consecutive doses of CV-B3/2035A (5 × 106 TCID50 per dose) or PBS (Mock) (n = 5 per group). Tumor growth (solid symbols) and body weight (open symbols) of the tumor-bearing mice were monitored over a 20-day period. Statistical analysis was performed by two-way ANOVA. Data are shown in means ± SD. Black arrows indicate treatments; ns, not significant

Back to article page